

Michaela Adamcova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8770406/publications.pdf>

Version: 2024-02-01

70
papers

2,266
citations

201674
27
h-index

223800
46
g-index

71
all docs

71
docs citations

71
times ranked

2810
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. <i>Clinical Science</i> , 2022, 136, 139-161.	4.3	1
2	Characteristics and outcomes of patients admitted for acute heart failure in a single-centre study. <i>ESC Heart Failure</i> , 2022, 9, 2249-2258.	3.1	6
3	Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 744-748.	1.9	11
4	Renin-Angiotensin-Aldosterone System: Friend or Foe? The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3217.	4.1	18
5	The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4762.	4.1	19
6	Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model <i>in vivo</i> . <i>Clinical Science</i> , 2021, 135, 1897-1914.	4.3	8
7	Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation. <i>Circulation: Heart Failure</i> , 2021, 14, e008209.	3.9	24
8	Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension. <i>Frontiers in Medicine</i> , 2020, 7, 325.	2.6	13
9	Antiarrhythmic Effects of Melatonin and Omega-3 Are Linked with Protection of Myocardial Cx43 Topology and Suppression of Fibrosis in Catecholamine Stressed Normotensive and Hypertensive Rats. <i>Antioxidants</i> , 2020, 9, 546.	5.1	28
10	Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II ² Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 402-415.	2.5	14
11	<i>In vitro</i> and <i>in vivo</i> investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. <i>Clinical Science</i> , 2019, 133, 1827-1844.	4.3	10
12	Lisinopril reverses behavioural alterations in spontaneously hypertensive rats. <i>General Physiology and Biophysics</i> , 2019, 38, 265-270.	0.9	2
13	Cardiac Troponins are Among Targets of Doxorubicin-Induced Cardiotoxicity in hiPCS-CMs. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2638.	4.1	15
14	79-...Effective cardioprotection against anthracycline cardiotoxicity in isolated cardiomyocytes and rabbits is based on dexrazoxane interaction with topoisomerase II beta instead of iron chelation by its metabolite ADR-925. , 2019, , .		0
15	What prevents cardioprotective drugs from reaching the market?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 463-465.	3.1	4
16	Multiplex biomarker approach to cardiovascular diseases. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1068-1072.	6.1	29
17	Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3017.	4.1	25
18	Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension. <i>Molecules</i> , 2018, 23, 265.	3.8	41

#	ARTICLE	IF	CITATIONS
19	Effect of melatonin on the behaviour of rats with continuous light-induced hypertension. <i>General Physiology and Biophysics</i> , 2018, 37, 469-473.	0.9	2
20	Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1612.	4.1	19
21	Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. <i>World Journal of Gastroenterology</i> , 2017, 23, 7678-7692.	3.3	13
22	Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?. <i>Toxicology</i> , 2016, 372, 52-63.	4.2	1
23	Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 91, 92-103.	1.9	20
24	Cardiac troponins as Translational biomarkers in cardiology: Theory and practice of cardiac troponin high-sensitivity assays. <i>BioFactors</i> , 2016, 42, 133-148.	5.4	12
25	Effects of captopril, spironolactone, and simvastatin on the cardiovascular system of non-diseased Wistar rats. <i>International Journal of Cardiology</i> , 2015, 190, 128-130.	1.7	6
26	Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. <i>International Journal of Cardiology</i> , 2015, 201, 358-367.	1.7	9
27	Hypertension and Cardiovascular Remodelling in Rats Exposed to Continuous Light: Protection by ACE-Inhibition and Melatonin. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	3.0	41
28	Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. <i>Journal of Pineal Research</i> , 2014, 57, 177-184.	7.4	70
29	Doxorubicin-induced behavioral disturbances in rats: Protective effect of melatonin and captopril. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 284-289.	2.9	31
30	Molecular Remodeling of Left and Right Ventricular Myocardium in Chronic Anthracycline Cardiotoxicity and Post-Treatment Follow Up. <i>PLoS ONE</i> , 2014, 9, e96055.	2.5	38
31	Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. <i>Toxicology</i> , 2013, 311, 191-204.	4.2	28
32	Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 468-478.	2.5	48
33	Proteomic insights into chronic anthracycline cardiotoxicity. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 50, 849-862.	1.9	57
34	Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment. <i>Journal of Hypertension</i> , 2010, 28, S19-S24.	0.5	15
35	Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril. <i>Journal of Hypertension</i> , 2010, 28, S13-S18.	0.5	43
36	Veterinary and toxicological applications for the detection of cardiac injury using cardiac troponin. <i>Veterinary Journal</i> , 2010, 185, 50-57.	1.7	81

#	ARTICLE	IF	CITATIONS
37	Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. <i>British Journal of Cancer</i> , 2009, 101, 792-802.	6.4	53
38	Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. <i>Pharmacological Reports</i> , 2009, 61, 154-171.	3.3	633
39	Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. <i>Journal of Hypertension</i> , 2009, 27, S11-S16.	0.5	35
40	Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2009, 27, S5-S10.	0.5	59
41	Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. <i>Acta Physiologica</i> , 2008, 194, 45-55.	3.8	30
42	Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. <i>British Journal of Pharmacology</i> , 2008, 155, 138-148.	5.4	42
43	Comparison of protection by salicylaldehyde isonicotinoyl hydrazone (SIH) against hydrogen peroxide- and anthracycline-induced toxicity to cardiac cells. <i>Toxicology Letters</i> , 2008, 180, S117.	0.8	0
44	Pyridoxal Isonicotinoyl Hydrazone (PIH) and its Analogs as Protectants Against Anthracycline-Induced Cardiotoxicity. <i>Hemoglobin</i> , 2008, 32, 207-215.	0.8	8
45	Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 326, 259-269.	2.5	43
46	Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH). <i>Toxicology</i> , 2007, 235, 150-166.	4.2	32
47	In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. <i>Toxicology</i> , 2007, 237, 218-228.	4.2	55
48	Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 1336-1347.	2.5	40
49	Cardiac remodeling and the role of matrix metalloproteinases in chronic anthracycline cardiotoxicity. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 1001.	1.9	1
50	Myocardial regulatory proteins and heart failure. <i>European Journal of Heart Failure</i> , 2006, 8, 333-342.	7.1	29
51	Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. <i>BioMetals</i> , 2005, 18, 163-169.	4.1	20
52	Troponin as a marker of myocardial damage in drug-induced cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 457-472.	2.4	64
53	Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. <i>Human and Experimental Toxicology</i> , 2005, 24, 581-589.	2.2	12
54	Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. <i>Pharmacological Research</i> , 2005, 51, 223-231.	7.1	39

#	ARTICLE	IF	CITATIONS
55	Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. <i>European Journal of Heart Failure</i> , 2004, 6, 377-387.	7.1	52
56	Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 431-434.	2.3	13
57	Troponins in children and neonates. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2003, 92, 1373-1375.	1.5	10
58	A Study of Potential Toxic Effects After Repeated 10-Week Administration of a New Iron Chelator "Salicylaldehyde Isonicotinoyl Hydrazone (SIH) to Rabbits. <i>Acta Medica (Hradec Kralove)</i> , 2003, 46, 163-170.	0.5	17
59	Protein and Phospholipids Composition of Human Myocardium in Children with Congenital Heart Disease. <i>Progress in Experimental Cardiology</i> , 2003, , 37-53.	0.0	1
60	Cardiac troponins following repeated administration of an iron chelator--salicylaldehyde isonicotinoyl hydrazone (SIH)--in rabbits. <i>Acta Medica (Hradec Kralove)</i> , 2003, 46, 171-4.	0.5	2
61	Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. <i>Human and Experimental Toxicology</i> , 2002, 21, 649-657.	2.2	36
62	Troponins for predicting cardiotoxic or cardioprotective effects of new drugs. <i>Journal of Molecular and Cellular Cardiology</i> , 2002, 34, A3.	1.9	0
63	Troponins in Experimental Studies. <i>Acta Medica (Hradec Kralove)</i> , 2002, 45, 29-32.	0.5	2
64	Troponins in experimental studies. <i>Acta Medica (Hradec Kralove)</i> , 2002, 45, 29-32.	0.5	2
65	Regulatory proteins in cardiac muscle of children with congenital heart diseases. <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, A1.	1.9	0
66	Protein profile of myocardium in children with congenital heart diseases. <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, A92.	1.9	1
67	Cardiac Troponin T in Neonates after Acute and Long-Term Tocolysis. <i>Neonatology</i> , 2000, 78, 288-292.	2.0	16
68	Anthracycline-Induced Cardiotoxicity. <i>Acta Medica (Hradec Kralove)</i> , 2000, 43, 75-82.	0.5	57
69	Cardiac troponin T in pregnant women having intravenous tocolytic therapy. <i>Archives of Gynecology and Obstetrics</i> , 1999, 262, 121-126.	1.7	21
70	Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. <i>Journal of Cancer Research and Clinical Oncology</i> , 1999, 125, 268-274.	2.5	39